VTGN
Vistagen Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.20
+1.55%Sep 24, 2026, 11:00 UTC
Vistagen presented positive exploratory data at Psych Congress 2026 in New Orleans supporting the potential of its intranasal pherine candidate fasedienol in very severe social anxiety disorder.
Source:Sep 22, 2026, 12:30 UTC
Vistagen announced preliminary positive data from the open-label extension portion of the PALISADE-4 Phase 3 study of fasedienol nasal spray for the acute treatment of social anxiety disorder, showing the drug was well-tolerated with no new drug-related safety findings after as-needed use for up to 12 months.
Sep 10, 2026, 12:30 UTC
Vistagen announced it will present a poster at Psych Congress 2026 highlighting a positive efficacy signal for its fasedienol nasal spray in study participants with very severe social anxiety disorder.
Source:Aug 14, 2026, 00:00 UTC
Vistagen Therapeutics reported Q1 FY2027 revenue of $1.476 million, up 504.9% year-over-year, with a net loss of $13.03 million and diluted EPS of -$0.30.
Aug 6, 2026, 12:30 UTC
Vistagen announced topline results from its exploratory Phase 2 repeat dose study of fasedienol nasal spray for social anxiety disorder, showing favorable safety and efficacy signals.
Source:Aug 4, 2026, 09:00 UTC
SRX Global Inc. announced on August 4, 2026 that it has acquired a stake in Vistagen Therapeutics, Inc.
Jul 31, 2026, 00:00 UTC
Vistagen Therapeutics appointed Douglas J. Williamson, M.D. as a director, effective July 29, 2026, with stock option compensation and eligibility for the Director Compensation Plan.
Jun 30, 2026, 17:35 UTC
Vistagen Inc. reported that its Phase 3 PALISADE-4 trial of intranasal fasedienol for social anxiety disorder did not meet its primary endpoint in the overall study population.
Source:Jun 15, 2026, 20:30 UTC
Vistagen reported financial results for its fiscal year ended March 31, 2026.
Source: